Arecor Therapeutics plc (LON:AREC) Insider Sarah Jennifer Howell Buys 21,077 Shares

Arecor Therapeutics plc (LON:AREC) insider Sarah Jennifer Howell bought 21,077 shares of the firm’s stock in a transaction on Monday, May 19th. The stock was purchased at an average price of GBX 47 ($0.63) per share, with a total value of £9,906.19 ($13,284.42).

Arecor Therapeutics Trading Down 4.3%

Arecor Therapeutics stock opened at GBX 41.15 ($0.55) on Thursday. The firm has a 50 day simple moving average of GBX 41.01 and a 200-day simple moving average of GBX 56.22. The company has a debt-to-equity ratio of 5.51, a current ratio of 1.37 and a quick ratio of 6.24. The stock has a market capitalization of £15.54 million, a PE ratio of -1.45 and a beta of -0.18. Arecor Therapeutics plc has a 12-month low of GBX 35.40 ($0.47) and a 12-month high of GBX 170 ($2.28).

Arecor Therapeutics (LON:AREC) last posted its quarterly earnings data on Tuesday, April 22nd. The company reported GBX (0.31) ($0.00) earnings per share (EPS) for the quarter. Arecor Therapeutics had a negative net margin of 176.89% and a negative return on equity of 118.67%. As a group, equities research analysts expect that Arecor Therapeutics plc will post -0.35 EPS for the current fiscal year.

About Arecor Therapeutics

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products.